MedPath

Short antithrombotic therapy after stent implantation in high bleeding risk patients

Not Applicable
Completed
Conditions
Patients with coronary artery disease and indication for PCI
Circulatory System
Atherosclerotic heart disease
Registration Number
ISRCTN65588717
Lead Sponsor
niversity Hospital of Muenster
Brief Summary

2020 Results article in https://pubmed.ncbi.nlm.nih.gov/31965195/ (added 27/09/2021)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
89
Inclusion Criteria

1. Implantation of at least one Biofreedom® stent for the treatment of significant CAD during the study period
2. At least one criterion for high risk bleeding

Exclusion Criteria

1. Aged <18 years
2. Current pregnancy
3. Underlying malignant disease
4. Active bleeding
5. Unable to give informed consent

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> 1. Safety of a short antithrombotic therapy after stent implantation, measured using a standardized questionnaire at a single follow-up timepoint<br> 2. Efficacy of short antithrombotic therapy, measured using a standardized questionnaire at a single follow-up timepoint<br>
Secondary Outcome Measures
NameTimeMethod
Risk factors for events (bleeding or thrombotic), measured using a standardized questionnaire at a single follow-up timepoint
© Copyright 2025. All Rights Reserved by MedPath